NewLink Brings Flavivirus 'Dream Team' To Zika
This article was originally published in Scrip
NewLink Genetics Corp. is not just another company jumping on the bandwagon of the latest global health crisis – in this case, the Zika virus, a mosquito-borne illness rapidly spreading throughout Central and South America and certain US territories, with the first continental US transmission of the disease reported on Feb. 2, which apparently involved sexual contact.
You may also be interested in...
Takeda is officially in the ballgame, joining the ranks of other firms like Sanofi Pasteur and GlaxoSmithKline, to find a vaccine against the Zika virus after snagging a US government R&D contract worth up to $312m.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.